Fierce Pharma September 20, 2024
In the latest supply deal on the active pharmaceutical ingredients (API) front, Gilead Sciences has tapped South Korea’s Yuhan to help produce its HIV meds in a deal worth $80.9 million.
The supply agreement runs through September 2025. The deal amount represents 5.8% of Yuhan’s latest yearly sales of 1.85 trillion Korean won ($1.4 billion), according to a filing.
Yuhan co-promotes several Gilead HIV drugs, including the blockbuster Biktarvy, in Korea. Yuhan’s shares jumped 15.9% on Friday following the disclosure.
The two have inked a similar deal before to provide the HIV API in Ireland back in 2018 for $45.3 million. More recently, Yuhan expanded its API CDMO business through its Yuhan Chemical subsidiary, which claims the largest API...
Today's Sponsors
Today's Sponsor